Literature DB >> 7818260

The trends in incidence of primary brain tumors in the population of Rochester, Minnesota.

K Radhakrishnan1, B Mokri, J E Parisi, W M O'Fallon, J Sunku, L T Kurland.   

Abstract

A number of reports have suggested an increasing incidence of primary brain tumors, especially malignant astrocytomas, in the elderly population. To investigate this issue, we analyzed the incidence and temporal trends of primary intracranial neoplasms diagnosed in the population of Rochester, Minnesota, over the 40 years between 1950 and 1990. The incidence of symptomatic primary brain tumors (excluding patients diagnosed incidentally at autopsy and by neuroimaging studies) increased from 9.5 per 100,000 population per year in 1950 to 1969 to 12.5 per 100,000 per year in 1970 to 1989; this change was not statistically significant (chi 2 trend, 1.89; p = 0.17). While the incidence of pituitary adenomas increased significantly between the two periods (chi 2 trend, 4.44; p = 0.04), the incidence trends of all gliomas, malignant astrocytomas, and meningiomas showed no change among persons younger than 65 years as well as those 65 years and older. The number of patients incidentally found to have neoplasms by neuroimaging studies increased in the recent 20-year period (chi 2 trend, 4.08; p = 0.04). The average age- and sex-adjusted incidence rates per 100,000 per year during the study period in the population of Rochester, Minnesota, for symptomatic tumors were 5.0 for all gliomas, 3.3 for malignant astrocytomas, 2.0 for meningiomas, and 2.4 for pituitary adenomas. In conclusion, our data indicate that the reported increase in the incidence of primary brain tumors is an artifact of improvement in diagnostic technology and practice.

Entities:  

Mesh:

Year:  1995        PMID: 7818260     DOI: 10.1002/ana.410370113

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  48 in total

1.  Effects of thalidomide on parameters involved in angiogenesis: an in vitro study.

Authors:  M Gelati; E Corsini; S Frigerio; B Pollo; G Broggi; D Croci; A Silvani; A Boiardi; A Salmaggi
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

2.  Spontaneous regression of one nonfunctioning pituitary macroadenoma associated with abnormal liver enzyme tests.

Authors:  Adele Bahar; Zahra Kashi; Arezoo Nowzari
Journal:  Caspian J Intern Med       Date:  2011

3.  Investigation of a cluster of pituitary adenomas in workers in the aluminum industry.

Authors:  M R Cullen; H Checkoway; B H Alexander
Journal:  Occup Environ Med       Date:  1996-11       Impact factor: 4.402

4.  Effective time window in reducing pituitary adenoma size by gamma knife radiosurgery.

Authors:  Henry Ka-Fung Mak; Shui-Wun Lai; Wenshu Qian; Stanley Xu; Elizabeth Tong; May Lee Vance; Edward Oldfield; John Jane; Jason Sheehan; Kelvin K W Yau; Max Wintermark
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

5.  Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program.

Authors:  Brad E Zacharia; Samuel S Bruce; Hannah Goldstein; Hani R Malone; Alfred I Neugut; Jeffrey N Bruce
Journal:  Neuro Oncol       Date:  2012-06-26       Impact factor: 12.300

6.  Work productivity and neuropsychological function in persons with skull base tumors.

Authors:  Bethany D Nugent; Jason Weimer; Chienwen J Choi; Cathy J Bradley; Catherine M Bender; Christopher M Ryan; Paul Gardner; Paula R Sherwood
Journal:  Neurooncol Pract       Date:  2014-09

7.  Cavernous Sinus Meningioma with Orbital Involvement: Algorithmic Decision-Making and Treatment Strategy.

Authors:  Amol Raheja; William T Couldwell
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-17

8.  Growth curve analysis of asymptomatic and symptomatic meningiomas.

Authors:  Satoshi Nakasu; Yoko Nakasu; Tadateru Fukami; Junya Jito; Kazuhiko Nozaki
Journal:  J Neurooncol       Date:  2010-08-05       Impact factor: 4.130

9.  Dynamics of central and peripheral immunomodulation in a murine glioma model.

Authors:  Benjamin C Kennedy; Lisa M Maier; Randy D'Amico; Christopher E Mandigo; Elizabeth J Fontana; Allen Waziri; Marcela C Assanah; Peter Canoll; Richard C E Anderson; David E Anderson; Jeffrey N Bruce
Journal:  BMC Immunol       Date:  2009-02-18       Impact factor: 3.615

10.  Bioluminescence imaging reveals inhibition of tumor cell proliferation by Alzheimer's amyloid beta protein.

Authors:  Hong Zhao; Jinmin Zhu; Kemi Cui; Xiaoyin Xu; Megan O'Brien; Kelvin K Wong; Santosh Kesari; Weiming Xia; Stephen T C Wong
Journal:  Cancer Cell Int       Date:  2009-06-01       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.